Summit Therapeutics Inc.
SMMT
Price:
$19
Market Cap:
$14.00B
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cam...[Read more]
Industry
Biotechnology
IPO Date
2015-03-05
Stock Exchange
NASDAQ
Ticker
SMMT
PE Ratio
[-82.61]
ROE
[-104.22%]
Current Ratio
[8.31]
Dividend Yield
[0%]
Enterprise Value
[13.94B]
Dividend History
The ROE as of December 2024 (TTM) for Summit Therapeutics Inc. (SMMT) is -104.22%
According to Summit Therapeutics Inc.’s latest financial reports and current stock price. The company's current ROE is -104.22%. This represents a change of 120.33% compared to the average of -47.30% of the last 4 quarters.
Summit Therapeutics Inc. (SMMT) Historical ROE (quarterly & annually)
How has SMMT ROE performed in the past?
The mean historical ROE of Summit Therapeutics Inc. over the last ten years is -65.85%. The current -104.22% ROE has changed 58.25% with respect to the historical average. Over the past ten years (40 quarters), SMMT's ROE was at its highest in in the July 2017 quarter at 312.03%. The ROE was at its lowest in in the March 2023 quarter at -1184.22%.
Average
-65.85%
Median
-69.27%
Minimum
-791.49%
Maximum
611.82%
Summit Therapeutics Inc. (SMMT) ROE by Quarter and Year
Discovering the peaks and valleys of Summit Therapeutics Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.25%
Maximum Annual ROE = 611.82%
Minimum Annual Increase = -856.65%
Minimum Annual ROE = -791.49%
| Year | ROE | Change |
|---|---|---|
| 2023 | -791.49% | 1.25% |
| 2022 | -58.73% | -43.22% |
| 2021 | -103.44% | 55.96% |
| 2020 | -66.32% | 69.71% |
| 2019 | -39.08% | -320.88% |
| 2019 | 17.69% | -124.50% |
| 2018 | -72.21% | -111.80% |
| 2017 | 611.82% | -856.65% |
| 2016 | -80.86% | 6.50% |
| 2015 | -75.93% | -40.66% |
Summit Therapeutics Inc. (SMMT) Average ROE
How has SMMT ROE performed in the past?
The current ROE of Summit Therapeutics Inc. (SMMT) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-317.89%
5-year avg
-211.81%
10-year avg
-65.85%
Summit Therapeutics Inc. (SMMT) ROE vs. Peers
How is SMMT’s ROE compared to its peers?
Summit Therapeutics Inc.’s ROE is greater than Nkarta, Inc. (-27.13%), greater than Cullinan Oncology, Inc. (-26.54%), greater than Kezar Life Sciences, Inc. (-59.73%), greater than Kronos Bio, Inc. (-64.55%), greater than ZyVersa Therapeutics, Inc. (-25512.50%), less than Ocean Biomedical, Inc. (42.06%), greater than Zura Bio Limited (-39.61%), greater than Elevation Oncology, Inc. (-59.73%), greater than Icosavax, Inc. (-20.22%), less than Phio Pharmaceuticals Corp. (0%), greater than Sonnet BioTherapeutics Holdings, Inc. (-134.57%), greater than 180 Life Sciences Corp. (-383.41%), greater than Cardio Diagnostics Holdings, Inc. (-559.06%), greater than null (-258.81%),
| Company | ROE | Market cap |
|---|---|---|
| -27.13% | $165.84M | |
| -26.54% | $714.45M | |
| -59.73% | $47.86M | |
| -64.55% | $57.32M | |
| -25512.50% | $2.70M | |
| 42.06% | $20.54M | |
| -39.61% | $151.48M | |
| -59.73% | $33.34M | |
| -20.22% | $769.04M | |
| 0% | $2.32M | |
| -134.57% | $4.27M | |
| -383.41% | $5.73M | |
| -559.06% | $40.84M | |
| -258.81% | $0 |
Build a custom stock screener for Summit Therapeutics Inc. (SMMT) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Summit Therapeutics Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Summit Therapeutics Inc. (SMMT) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Summit Therapeutics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Summit Therapeutics Inc.'s ROE?
How is the ROE calculated for Summit Therapeutics Inc. (SMMT)?
What is the highest ROE for Summit Therapeutics Inc. (SMMT)?
What is the 3-year average ROE for Summit Therapeutics Inc. (SMMT)?
What is the 5-year average ROE for Summit Therapeutics Inc. (SMMT)?
How does the current ROE for Summit Therapeutics Inc. (SMMT) compare to its historical average?